Analgesia Induced by Dietary Restriction Is Mediated by the κ-Opioid System

Journal of Neuroscience

Volumn 23, Issue 35, 2003, Pages 11120-11126

  De Los Santos Arteaga, Mercedes ^a   Sierra Domínguez, Sergio A ^a   Fontanella, German H ^a   Delgado García, José M ^a   Carrión, Ángel M ^a  

^a UNIVERSIDAD PABLO DE OLAVIDE   (Spain)

Author keywords

C Fos; DREAM; Dynorphin; Intermittent fast diet; Pain relief; Spinal cord

Indexed keywords

17 METHYLNALOXONE; 3 METHOXYNALTREXONE; ACETIC ACID; DYNORPHIN; KAPPA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR ANTAGONIST; MESSENGER RNA; NALOXONAZINE; NALOXONE; NORBINALTORPHIMINE; PRODYNORPHIN; UNCLASSIFIED DRUG;

ANALGESIA; ANIMAL BEHAVIOR; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DIET RESTRICTION; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; LOCOMOTION; MALE; MOUSE; NOCICEPTION; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE C FOS; PAIN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPINAL CORD; SPINAL CORD DORSAL HORN;

EID: 0347379834     PISSN: 02706474     EISSN: None     Source Type: Journal    
DOI: 10.1523/jneurosci.23-35-11120.2003     Document Type: Article

References (42)

1. Akil H, Meng F, Mansour A, Thompson R, Xie GX, Watson S (1996) Cloning and characterization of multiple opioid receptors. NIDA Res Monogr 161:127-140.
2. Anson RM, Guo Z, de Cabo R, Iyun T, Rios M, Hagepanos A, Ingram DK, Lane MA, Mattson MP (2003) Intermittent fasting dissociates beneficial effects of dietary restriction on glucose metabolism and neuronal resistance to injury from calorie intake. Proc Natl Acad Sci USA 100:2616-2620.
3. Bie B, Pan ZZ (2003) Presynaptic mechanism for anti-analgesic and anti-hyperalgesic actions of κ-opioid receptors. J Neurosci 23:7262-7268.
4. Brochu M, Poehlman ET, Ades PA (2000) Obesity, body fat distribution, and coronary artery disease. J Cardiopulm Rehabil 20:96-108.
5. Campos D, Jiménez-Díaz L, Naranjo JR, Carrión AM (2003) Ca-dependent prodynorphin transcriptional derepression in neuroblastoma cells is exerted through DREAM protein activity in a kinase-independent manner. Mol Cell Neurosci 22:135-145.
6. Cao YQ, Mantyh PW, Carlson EJ, Gillespie AM, Epstein CJ, Basbaum AI (1998) Primary afferent tachykinins are required to experience moderate to intense pain. Nature 392:390-394.
7. Carrión AM, Mellström B, Naranjo JR (1998a) Protein kinase A-dependent transcriptional derepression of the human prodynorphin gene via differential binding to an intragenic silencer element. Mol Cell Biol 18:6921-6929.
8. Carrión AM, Mellström B, Luckman SM, Naranjo JR (1998b) Stimulus-specific hierarchy of enhancer elements within the rat prodynorphin promoter. J Neurochem 70:914-921.
9. 2+-regulated transcriptional repressor. Nature 398:80-84.
10. Caudle RM, Mannes AJ (2000) Dynorphin: friend or foe? Pain 87:235-239.
11. Cheng HY, Pitcher GM, Laviolette SR, Whishaw IQ, Tong KI, Kockeritz LK, Wada T, Joza NA, Cracower M, Goncalves J, Sarosi I, Woodgett JR, Oliveira-dos-Santos AJ, Ikura M, van der Kooy D, Salter MW, Penninger JM (2002) DREAM is a critical transcriptional repressor for pain modulation. Cell 108:31-43.
12. Cole RL, Konradi C, Douglass J, Hyman SE (1995) Neuronal adaptation to amphetamine and dopamine: molecular mechanism of prodynorphin gene regulation in rat striatum. Neuron 14:813-823.
13. Costigan M, Woolf CJ (2002) No DREAM, no pain: closing the spinal gate. Cell 108:197-200.
14. Dickenson AH (1991) Mechanisms of the analgesic actions of opiates and opioids. Br Med Bull 47:690-702.
15. Grudt TJ, Williams JT (1993) κ-Opioid receptors also increase potassium conductance. Proc Natl Acad Sci USA 90:11429-11432.
16. Hauser KF, Foldes JK, Turbek CS (1999) Dynorphin A (1-13) neurotoxicity in vitro: opioid and non-opioid mechanisms in mouse spinal cord neurons. Exp Neurol 160:361-375.
17. Herdegen T, Kovary K, Leah J, Bravo R (1991) Specific temporal and spatial distribution of Jun, Fos, and Krox-24 proteins in spinal neurons following nociceptive trans-synaptic stimulation. J Comp Neurol 313:178-191.
18. Hunt SP, Pini A, Evan G (1987) Induction of c-Fos-like protein in spinal cord neurons following sensory stimulation. Nature 328:632-634.
19. Iadarola MJ, Brady LS, Draisci G, Dubner R (1988) Enhancement of dynorphin gene expression in spinal cord following experimental inflammation: stimulus specificity, behavioral parameters and opioid receptor binding. Pain 35:313-326.
20. Kajander KC, Sahara Y, Iadarola MJ, Bennett GJ (1990) Dynorphin increases in the dorsal spinal cord in rats with a painful peripheral neuropathy. Peptides 11:719-728.
21. Laughlin TM, Larson AA, Wilcox GL (2001) Mechanisms of induction of persistent nociception by dynorphin. J Pharmacol Exp Ther 299:6-11.
22. Lebovitz HE (1999) Type II diabetes: an overview. Clin Chem 45:1339-1345.
23. Ledo F, Carrión AM, Link WA, Mellström B, Naranjo JR (2000) DREAM-αCREM interaction via leucine-charged domains derepresses downstream regulatory element-dependent transcription. Mol Cell Biol 20:9120-9126.
24. Levi F (1999) Cancer prevention: epidemiology and perspectives. Eur J Cancer 35:1912-1924.
25. Maeda H, Glesier CA, Masoro EJ, Murata I, McMahan CA, Yu BP (1985) Nutritional influences of aging in Fisher 344 rats. II. Pathology. J Gerontol 40:671-688.
26. Mattson MP, Duan W, Lee J, Guo Z (2001) Suppression of brain aging and neurodegenerative disorder by dietary restriction and environmental enrichment: molecular mechanisms. Mech Ageing Dev 122:757-778.
27. McLaughlin JP, Marton-Popovici M, Chavkin C (2003) k-Opioid receptor antagonism and prodynorphin gene disruption block stress-induced behavioral responses. J Neurosci 23:5674-5683.
28. Morgan JI, Curran T (1991) Stimulus-transcription coupling in the central nervous system: involvement of the inducible proto-oncogenes fos and jun. Annu Rev Neurosci 14:421-451.
29. Munglani R, Hunt SP (1995) Proto-oncogenes: basic concepts and stimulation induced changes in the spinal cord. Prog Brain Res 104:283-298.
30. Naranjo JR, Mellström B, Achaval M, Sassone-Corsi P (1991) Molecular pathways of pain: Fos/Jun-mediated activation of the prodynorphin gene through a non-canonical AP-1 site. Neuron 6:607-617.
31. Ogura M, Kita H (2000) Dynorphin exerts both post synaptic and presynaptic effects in the globus pallidus of the rat. J Neurophysiol 83:3366-3376.
32. Raffoul JJ, Guo Z, Soofi A, Heydari AR (1999) Caloric restriction and genomic stability. J Nutr Health Aging 3:102-110.
33. Randic M, Cheng G, Kojic L (1995) κ-Opioid receptor agonists modulate excitatory transmission in substantia gelatinosa of the rat spinal cord. J Neurosci 15:6809-6826.
34. Rubinstein M, Mogil JS, Japon M, Chan EC, Allen RG, Low MJ (1996) Absence of opioids stress-induced analgesia in mice lacking β-endorphin by site-directed mutagenesis. Proc Natl Acad Sci USA 93:3995-4000.
35. 2+ currents and secretion in isolated neuroendocrine nerve terminals. J Neurosci 17:6565-6574.
36. Spaulding CC, Walford RL, Effros RB (1997) Caloric restriction inhibits the age-related dysregulation of the cytokines TNF-alpha and IL-6 in C3B10RF1 mice. Mech Ageing Dev 93:87-97.
37. Suzuki R, Chapman V, Dickenson AH (1999) The effectiveness of spinal and systemic morphine on rat dorsal horn neuronal responses in the spinal nerve ligation model of neuropathic pain. Pain 80:215-228.
38. Taylor J, Mellström B, Fernaud I, Naranjo JR (1998) Metamizol potentiates morphine effects on visceral pain and evoked c-Fos immunoreactivity in spinal cord. Eur J Pharmacology 351:39-47.
39. Vaccarino AL, Kastin AJ (2000) Endogenous opiates: 1999. Peptides 21:1975-2034.
40. Wiley JW, Moises HC, Gross RA, MacDonald RL (1997) Dynorphin A-mediated reduction in multiple calcium currents involves a Go alpha-subtype G protein in rat primary afferent neurons. J Neurophysiol 77:1338-1348.
41. Woolf CJ, Salter MW (2000) Neuronal plasticity: increasing the gain in pain. Science 288:1765-1769.
42. Zachariou V, Goldstein BD (1997) Dynorphin-(1-8) inhibits the release of substance P-like immunoreactivity in the spinal cord of rats following a nociceptive mechanical stimulus. Eur J Pharmacol 323:159-165.